BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.7%

Neg 0% Neu 91.7% Pos 0%

BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.

Comments

No comments yet. Be the first!